Stoke Therapeutics (STOK) Cash from Financing Activities (2018 - 2026)

Stoke Therapeutics' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $84.3 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 6037.34% year-over-year to $84.3 million in Q1 2026; TTM through Mar 2026 was $180.3 million, a 37.93% increase from a year earlier, with the FY2025 full-year figure at $97.4 million, down 25.71% from the prior year.
• Cash from Financing Activities declined to $84.3 million in Q1 2026 per STOK's latest filing, from $92.3 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $120.6 million in Q2 2024 and bottomed at $43000.0 in Q4 2022.
• The 5-year median for Cash from Financing Activities is $3.1 million (2025), against an average of $24.2 million.
• Across the five-year window, Cash from Financing Activities soared 251254.17% in 2024 and plunged 99.54% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $43000.0 in 2022, then soared by 16976.74% to $7.3 million in 2023, then sank by 92.26% to $568000.0 in 2024, then soared by 16157.22% to $92.3 million in 2025, then fell by 8.68% to $84.3 million in 2026.
• Per Business Quant, the three latest STOK Cash from Financing Activities figures stand at $84.3 million (Q1 2026), $92.3 million (Q4 2025), and $3.1 million (Q3 2025).